PharmaCyte Biotech, Inc. — Director's Dealing 2021

Aug 21, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PharmaCyte Biotech, Inc. (PMCB)
CIK: 0001157075
Period of Report: 2021-08-10

Reporting Person: Abecassis Michael M (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1667	Direct
Common Stock	800	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$87.00	2022-07-03	Common Stock (334)		Direct
Stock Option (right to buy)	$87.00	2022-07-03	Common Stock (800)		Indirect
Stock Option (right to buy)	$102.45	2023-07-01	Common Stock (334)		Direct
Stock Option (right to buy)	$55.50	2024-07-01	Common Stock (334)		Direct
Stock Option (right to buy)	$37.05	2025-07-01	Common Stock (334)		Direct
Stock Option (right to buy)	$16.20	2026-06-30	Common Stock (334)		Direct

Footnotes

F1: The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").

F2: The exercise price has been adjusted to reflect the Reverse Split.